Mallinckrodt completed the merger with Endo in a $6.7bn deal.

Mallinckrodt, an American-Irish domiciled manufacturer of specialty pharmaceuticals, completed the merger with Endo, an American diversified pharmaceutical company, in a $6.7bn deal. "We are excited to pursue a promising new future for all the stakeholders of Mallinckrodt and Endo. We commend the employees of both companies for the extraordinary effort required to achieve this milestone. Today we bring together two highly complementary companies with durable, on-market products in our branded portfolio and best-in-class capabilities across the value chain in our generics and sterile injectables business, which we call Par Health. We have a strong balance sheet and meaningful financial flexibility to invest in innovation and business development to drive growth. As a company deeply committed to operating with integrity and purpose, we are focused on delivering significant value to shareholders and employees for the ultimate benefit of the patients we serve," Siggi Olafsson, the combined company President and CEO.